Analysts expect Recro Pharma Inc (NASDAQ:REPH) to post sales of $16.81 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Recro Pharma’s earnings, with the lowest sales estimate coming in at $16.27 million and the highest estimate coming in at $17.40 million. Recro Pharma reported sales of $16.93 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 0.7%. The business is scheduled to announce its next earnings report on Thursday, August 9th.
According to Zacks, analysts expect that Recro Pharma will report full year sales of $70.88 million for the current year, with estimates ranging from $70.74 million to $71.10 million. For the next financial year, analysts anticipate that the company will post sales of $76.24 million per share, with estimates ranging from $69.10 million to $84.37 million. Zacks’ sales averages are an average based on a survey of research analysts that cover Recro Pharma.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.03. The business had revenue of $19.54 million during the quarter, compared to the consensus estimate of $17.32 million. Recro Pharma had a negative net margin of 74.85% and a negative return on equity of 105.78%.
Several brokerages have recently weighed in on REPH. ValuEngine upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating in a research note on Wednesday, April 18th. Berenberg Bank began coverage on shares of Recro Pharma in a research note on Thursday, April 19th. They issued a “buy” rating for the company. Zacks Investment Research upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, March 21st. Oppenheimer restated a “buy” rating on shares of Recro Pharma in a research note on Friday, March 23rd. Finally, CIBC began coverage on shares of Recro Pharma in a research note on Wednesday, February 14th. They issued an “outperform” rating and a $19.00 target price for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. Recro Pharma presently has an average rating of “Buy” and a consensus price target of $12.63.
In other Recro Pharma news, major shareholder Healthcare Master Fun Broadfin sold 188,000 shares of the stock in a transaction on Thursday, May 24th. The shares were sold at an average price of $5.81, for a total transaction of $1,092,280.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 21.60% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Jump Trading LLC bought a new position in Recro Pharma during the 1st quarter valued at $124,000. Citadel Advisors LLC bought a new position in Recro Pharma during the 1st quarter valued at $126,000. Cubist Systematic Strategies LLC bought a new position in Recro Pharma during the 1st quarter valued at $139,000. Two Sigma Investments LP bought a new position in Recro Pharma during the 4th quarter valued at $164,000. Finally, Strs Ohio boosted its stake in Recro Pharma by 455.0% during the 4th quarter. Strs Ohio now owns 22,200 shares of the specialty pharmaceutical company’s stock valued at $205,000 after acquiring an additional 18,200 shares during the last quarter. Hedge funds and other institutional investors own 56.15% of the company’s stock.
Shares of Recro Pharma traded down $0.01, hitting $5.29, on Monday, Marketbeat reports. The stock had a trading volume of 253,958 shares, compared to its average volume of 811,915. The company has a market capitalization of $108.69 million, a PE ratio of -2.66 and a beta of -0.97. The company has a current ratio of 1.78, a quick ratio of 1.55 and a debt-to-equity ratio of 2.20. Recro Pharma has a 52-week low of $5.00 and a 52-week high of $13.05.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.